mirtazapine has been researched along with CACH Syndrome in 1 studies
Mirtazapine: A piperazinoazepine tetracyclic compound that enhances the release of NOREPINEPHRINE and SEROTONIN through blockage of presynaptic ALPHA-2 ADRENERGIC RECEPTORS. It also blocks both 5-HT2 and 5-HT3 serotonin receptors and is a potent HISTAMINE H1 RECEPTOR antagonist. It is used for the treatment of depression, and may also be useful for the treatment of anxiety disorders.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Holyoak, AL | 1 |
| Trout, MJ | 1 |
| White, RP | 1 |
| Prematuranga, S | 1 |
| Senthuran, S | 1 |
1 other study available for mirtazapine and CACH Syndrome
| Article | Year |
|---|---|
Toxic leukoencephalopathy in the intensive care unit.
Topics: Adult; Amphetamines; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Ascorbic Acid; Brain; C | 2014 |